Nuvalent Q2 net loss $29.1M; cash $431.2M; NVL-655 data expected Q4 2023

Nuvalent, Inc.

2023-Q2 EPS reported -$0.96

Net loss $29.1M ($0.51/share); R&D $25.9M, G&A $8.1M for Q2 2023.
Cash, cash equivalents and marketable securities $431.2M as of June 30, 2023; runway into H2 2025.
Preliminary dose-escalation data for NVL-655 from ALKOVE-1 trial expected at medical meeting in Q4 2023.
NVL-520 ARROS-1 trial progressing toward RP2D; NVL-330 HER2 inhibitor advancing through IND-enabling studies.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Nuvalent, Inc. reported second quarter 2023 results: net income $29.1 million, or $0.51 per share.

Period: second quarter 2023
Net income: $29.1 million, or $0.51 per share
Result: reported results

Exact text from the filing

Net loss for the second quarter of 2023 was $29.1 million, or $0.51 per share.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Nuvalent, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-040936

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.